Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research

This publication has 33 references indexed in Scilit:

• Dynamics of Polymorphism in a Malaria Vaccine Antigen at a Vaccine-Testing Site in Mali
  PLoS Medicine, 2007
• Enhancement of functional antibody responses to AMA1-C1/Alhydrogel®, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide
  Vaccine, 2006
• Malaria vaccines in development
  Emerging Drugs, 2005
• High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya
  Vaccine, 2005
• Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research
  Vaccine, 2005
• Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria
  Vaccine, 2004
• Transcription status of vaccine candidate genes of Plasmodium falciparum during the hepatic phase of its life cycle
  Zeitschrift Fur Parasitenkunde-Parasitology Research, 2004
• Induction of Parasite Growth-Inhibitory Antibodies by a Virosomal Formulation of a Peptidomimetic of Loop I from Domain III of Plasmodium falciparum Apical Membrane Antigen 1
  Infection and Immunity, 2003
• High-Level Expression of the Malaria Blood-Stage Vaccine Candidate Plasmodium falciparum Apical Membrane Antigen 1 and Induction of Antibodies That Inhibit Erythrocyte Invasion
  Infection and Immunity, 2002
• Purification, Characterization, and Immunogenicity of the Refolded Ectodomain of the Plasmodium falciparum Apical Membrane Antigen 1 Expressed in Escherichia coli
  Infection and Immunity, 2002